Q-linea AB (QLINEA) Price & Analysis

Compare

2 Followers

QLINEA Stock Chart & Stats

Day’s Range― - ―

52-Week Rangekr28.00 - kr986.15

Previous CloseN/A

Volume6.05M

Average Volume (3M)10.45K

Market Cap

€180.20M

Enterprise Valuekr254.53M

Total Cash (Recent Filing)€82.71M

Total Debt (Recent Filing)€49.20M

Price to Earnings (P/E)―

Beta3.15

Next Earnings

Oct 30, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-9.13

Shares Outstanding6,436,873

10 Day Avg. Volume19,470

30 Day Avg. Volume10,453

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€50.67

Price Target Upside71.76% Upside

Rating ConsensusHold

Number of Analyst Covering1

Q-linea AB News

Q-linea Announces SEK 322 Million Rights Issue to Boost Market Expansion

An update from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea AB has announced a rights issue...

2d ago

Q-linea Outlines Strategic Growth and Cost Reduction Plans

Q-linea AB ( ($SE:QLINEA) ) has issued an update. Q-linea AB announced a strategic update, emphasizing its goal...

2d ago

Q-linea AB Calls Extraordinary Meeting for Share Issue

The latest update is out from Q-linea AB ( ($SE:QLINEA) ). Q-linea AB has announced an extraordinary general...

2d ago

Q-linea Faces Setback in ESTAR Tender but Remains Optimistic

Q-linea AB ( ($SE:QLINEA) ) has shared an announcement. Q-linea AB announced that the Italian Supreme Administrative Court...

10d ago

Q-linea Expands ASTar Clinical Evaluations to GCC Region

Q-linea AB ( ($SE:QLINEA) ) has issued an update. Q-linea AB has announced the initiation of two new...

15d ago

Q-linea AB Announces Share Restructuring

Q-linea AB ( ($SE:QLINEA) ) has provided an announcement. Q-linea AB has announced a change in the number...

2M ago

BLASTID and Q-linea Showcase Breakthrough in Rapid Sepsis Diagnosis

Q-linea AB ( ($SE:QLINEA) ) just unveiled an announcement. BLASTID and Q-linea have announced a successful proof-of-concept for...

2M ago

Q-linea AB Reports Strong Q2 2025 Progress in ASTar Commercialization

Q-linea AB ( ($SE:QLINEA) ) has provided an update. Q-linea AB’s Q2 2025 interim report highlights significant progress...

2M ago

Q-linea Adjusts Reverse Share Split Timetable

Q-linea AB ( ($SE:QLINEA) ) has provided an update. Q-linea AB announced a correction to its previously released...

2M ago

Q-linea AB Announces Reverse Share Split Effective July 2025

Q-linea AB ( ($SE:QLINEA) ) has shared an announcement. Q-linea AB has announced a reverse share split, consolidating...

2M ago

QLINEA FAQ

What was Q-linea AB’s price range in the past 12 months?

Q-linea AB lowest stock price was kr28.00 and its highest was kr986.15 in the past 12 months.

What is Q-linea AB’s market cap?

Q-linea AB’s market cap is €180.20M.

When is Q-linea AB’s upcoming earnings report date?

Q-linea AB’s upcoming earnings report date is Oct 30, 2025 which is in 40 days.

How were Q-linea AB’s earnings last quarter?

Q-linea AB released its earnings results on Jul 10, 2025. The company reported -kr9.13 earnings per share for the quarter, missing the consensus estimate of N/A by -kr9.13.

Is Q-linea AB overvalued?

According to Wall Street analysts Q-linea AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Q-linea AB pay dividends?

Q-linea AB does not currently pay dividends.

What is Q-linea AB’s EPS estimate?

Q-linea AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Q-linea AB have?

Q-linea AB has 6,436,873 shares outstanding.

What happened to Q-linea AB’s price movement after its last earnings report?

Q-linea AB reported an EPS of -kr9.13 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.955%.

Which hedge fund is a major shareholder of Q-linea AB?

Currently, no hedge funds are holding shares in SE:QLINEA

Company Description

Q-linea AB

Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.

Q-linea AB (QLINEA) Earnings & Revenues

Historic Earnings Reports

QLINEA Stock 12 Month Forecast

Average Price Target

kr50.67

▲(71.76% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"kr35","155":"kr155","275":"kr275","395":"kr395","515":"kr515"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50.71076231990328,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr50.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.6682493506,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr50.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.71076231990328,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr50.71</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,155,275,395,515],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.4,53.19313556306948,52.986271126138966,52.77940668920845,52.572542252277934,52.36567781534742,52.1588133784169,51.95194894148638,51.74508450455586,51.538220067625346,51.33135563069483,51.124491193764314,50.9176267568338,{"y":50.71076231990328,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.4,53.18986533466154,52.979730669323075,52.76959600398462,52.55946133864615,52.349326673307694,52.13919200796923,51.92905734263077,51.718922677292305,51.50878801195385,51.29865334661538,51.08851868127692,50.878384015938465,{"y":50.6682493506,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.4,53.19313556306948,52.986271126138966,52.77940668920845,52.572542252277934,52.36567781534742,52.1588133784169,51.95194894148638,51.74508450455586,51.538220067625346,51.33135563069483,51.124491193764314,50.9176267568338,{"y":50.71076231990328,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":514.312,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":399.706,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":349.477,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":174.597,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":97.627,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":330,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":56,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.8,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":36,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":46.1,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":46.1,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.8,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":53.4,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >